MARKET OVERVIEW
Glucagon is a medication used to manage and treat hypoglycemia as an antidote to beta-blocker and calcium channel blocker overdose, anaphylaxis refractory to epinephrine, and aid in passing food bolus. It is an anti-hypoglucemic class of medications with the activity describing the indications, actions, and contraindications for glucagon as a valuable agent for managing acute hypoglycemia, beta-blocker, and calcoun channel blocker overdose, refractory anaphylaxis, and esophageal obstruction due to foof bolus. Additionally, such glucagon activity highlights the mechanism of action, adverse event profile, and other key factors (e.g., off-label use, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to healthcare team members in managing patients with indicated conditions.
MARKET SCOPE
The "Global Glucagon Therapy Market Analysis to 2028" is a specialized and in-depth examination of the healthcare industry, with a particular emphasis on global market trend analysis. The purpose of this report is to provide an overview of the glucagon therapy market, as well as detailed market segmentation based on product, application, and end user. Additionally, the report offers key statistics on the market status of the leading glucagon therapy market players, as well as key market trends and opportunities.
MARKET SEGMENTATION
- Based on product, the market is bifurcated into injectable and nasal.
- Based on application, the market is segregated as general use, diagnostics & mobility, cardiogenic shock, and others.
- Based on end user, the market is classified into hospitals and specialty clinics.
MARKET DYNAMICS
Drivers
- Rising number of people suffering from heart problems is one of the most influential factors responsible for the growth of global glucagon therapy market.
- Changing lifestyle and unhealthy eating habits have gained significant attention in the market responsible for the ultimate growth.
Restraint
- Lack of awareness for understanding the significance of glucose management acts as the most impactful factors responsible for the sluggish growth of overall market.
REGIONAL FRAMEWORK
The report offers a comprehensive overview of the industry, including both qualitative and quantitative data. It provides a global market overview and forecast based on various segments. It also provides market size and forecast estimates for five major regions, namely North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America (SACA), from 2019 to 2028. Each region's glucagon therapy market is further subdivided by respective countries and segments. The report analyses and forecasts 18 countries globally, as well as the current trend and opportunities in the region.
The report analyses market factors affecting both the demand and supply sides, as well as market dynamics affecting the market during the forecast period, such as drivers, restraints, opportunities, and future trends. The report also includes a comprehensive PEST analysis for each of the five regions, namely North America, Europe, APAC, MEA, and South and Central America after assessing the political, economic, social, and technological factors influencing the glucagon therapy market in these regions.
Impact of COVID-19 on Glucagon therapy Market
Clinical studies have proven promising results on the utilization of antivirals for pandemic situations like SARS-CoV-2 and other RNA virus infections by targeting the critical enzymes of SARS-CoV-2 by reducing the viral load and viral shedding. The interaction between diabetes and COVID-19 is still evolving. Therefore, research clearly established the role of ACE2 and the increased severity of COVID-19 infections among patients with diabetes. Additionally, the role of DPP4 is implicated in MERS-CoV pathogenesis, which may be implicated in SARS-CoV-2 as they belong to the same subfamily and family. On the other hand, anti-diabetic drugs can reduce the processes and achieve good glycemic control, among which insulin is of special importance in managing COVId-19 patients suffering from diabetes, particularly those suffering from hyperglycemic emergencies or in ICU patient admissions. Such aforementioned factors may be responsible for the overall market growth amid COVID-19 patients during the forecast period of 2022-2028.
MARKET PLAYERS
The report covers key developments in the glucagon therapy market with focus on two main strategies such as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies that includes new product launches, product approvals by the authorized bodies, and others such as patents and events. Inorganic growth strategies activities normally includes strategic acquisitions, and partnership & collaborations between the companies. These activities have paved way for the expansion of business and customer base of market players. The market payers from glucagon therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for glucagon therapy in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the glucagon therapy market. Also, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, and the key development in the past five years.
- Xeris Biopharma Holdings, Inc.
- SVAR
- Novo Nordisk A/S
- Elli Lilly
- Taj Pharmaceuticals Limited
- Fresenius Kabi
- Torrent Pharmaceuticals Limited
- Ferozsons Laboratories Limited
- Zealand Pharma A/S
- Amphastar Pharmaceuticals, Inc.
The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.